AbbVie stock weekly forecast: Upward momentum continues amid positive sentiment and Apogee acquisition

AbbVie stock weekly forecast: Upward momentum continues amid positive sentiment and Apogee acquisition
AbbVie gains 1.54% over the week

Shares of AbbVie Inc. (ABBV) are holding near $260 after gaining just over 1.5% over the past week as buyers keep control. Momentum has been supported by steady inflows and positive sentiment, setting the stage for a test of key resistance levels into the coming week.

ABBV price prediction
24H -0.39%
$293.89
48H -0.2%
$294.44
7D -0.15%
$294.6
1M 3.49%
$305.33
3M 11.89%
$330.12
6M 4.9%
$309.49
12M 26.84%
$374.21
Current price: $295.03 0.5400 0.18%
Closed 11/13
Daily range 293.73 Arrow from to Icon 297.20
Weekly range 289.62 Arrow from to Icon 300.31
Loading...

Highlights

  • Shares of AbbVie gained $4.24 over the past 7 days, currently trading at $259.71 in a bullish long-term trend.
  • The stock holds above key short-term support with indicators showing continued upward momentum and overbought signals.
  • Expected trading range for the next five days is $247.97 to $264.29, with a decisive break above $262.81 opening the path to further gains.

Acquisition-driven EPS cut offsets are highlighted as pipeline news sways sentiment

AbbVie finalized its $10.9 billion acquisition of Apogee Therapeutics on September 3, 2026, according to PR Newswire, integrating Apogee’s inflammatory disease portfolio into the company. AbbVie also reduced its 2026 full-year adjusted EPS outlook by $0.04 at the midpoint, citing short-term dilution from the Apogee deal, partially offset by strong business performance, as noted by Yahoo Finance. Additional pipeline developments include positive topline results from the Phase 3 CERVINO study and a regulatory filing in Europe for Skyrizi’s expanded use in Crohn’s disease.

AbbVie Inc. asset chart
AbbVie Inc. price dynamics. Source: TradingView.

Overbought momentum builds as MACD signals bullish potential against key resistance

The daily chart reveals AbbVie in the upper part of its recent range, supported by a 7-day volatility of 4.06%. The MACD continues to indicate a strong buy bias, while the Bull/Bear Power reflects an overbought condition, and ADX shows supportive upward momentum. Nearest support is seen at $256.18 and the Ichimoku Kijun at $254.34, while immediate resistance stands at $262.81. This setup points to an emerging move higher that is not yet confirmed, with price action closely tracking resistance levels.

Breakout risk rises as high probability of gains defines next week’s range

For the next five trading days, the expected range is $247.97 to $264.29. There is a very high probability of an increase and a very low probability of a decrease. The base case sees the stock remaining between support at $256.18 and resistance at $262.81. A decisive break above $262.81 could lead to further gains toward the higher end of the range, while a move below $256.18 would expose downside risk toward $254.34 and potentially lower.

Jainam Mehta, market strategist, notes that shares of AbbVie ended the week near $260, helped by sustained inflows and constructive sentiment. The finalized $10.9 billion Apogee Therapeutics acquisition and strong pipeline updates have supported a positive narrative, though management flagged a modest EPS trim for 2026 due to short-term deal dilution. Technically, ABBV sits close to resistance at $262.81 with clear signs of upward momentum, but a persistently overbought daily reading demands discipline. "If buyers manage a sustained close above $262.81 this week, I see scope for additional upside, but I won’t chase strength until that breakout is confirmed."

Previously it was reported that AbbVie's technical outlook was dependent on resolving key support and resistance levels, with mixed signals leaving the trend unconfirmed. The current update adds further context with the Apogee acquisition and recent pipeline progress, highlighting $262.81 as a crucial resistance level to monitor for confirmation of sustained upward momentum in the days ahead.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.